The era of CFTR modulators: improvements made and remaining challenges

Abstract excerpt

The entry into the clinic of CFTR modulators such as TRIKAFTA has significantly improved life for ∼90% CF patients carrying one or two F508del mutations but challenges remain for rare CFTR mutations and the management of lung infections @SaraOcana1https://bit.ly/3aRafQF

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cystic Fibrosis Research Advances
• Share to Neonatal Respiratory Health Research
• Share to Tracheal and airway disorders